So far 2011 has been a banner year for recoveries under the False Claims Act. Nearly $6 billion has been recovered to date including:
Glaxo agreeing to pay $3 billion
Abbott agreeing to pay $1.3 billion
Merck agreeing to pay $950 million
Oracle agreeing to pay $200 million
Sandoz agreeing to pay $150 million
Maxim agreeing to pay $150 million
New York City agreeing to pay $70 million
LHC Groups (home health) agreeing to pay $65 million.
Another $2 Billion is certainly possible. Here’s a look at what’s ahead:
Risperdal: Johnson & Johnson “tentatively agreed to settle a single misdemeanor criminal charge: related to Risperdal” this past August. A formal civil and criminal settlement is likely to follow and likely to be in the $1 billion range.
Agility/Public Warehouse:
This is a big FCA case related to the Iraq war. Agility is a Kuwati-owned contractor that has now been excluded from doing business with the United States. Settlement negotiations have been ongoing for sometime and are continuing. Estimates are for a settlement in the range of $650 million.
Ranbaxy:
This company had serious quality control and manufacturing problems at its pharmaceutical plant. The Food and Drug Administration has accused Ranbaxy of “a pattern of systemic fraudulent conduct” over a period of years. Ranbaxy is accused of fabricating data in drug applications, taking shortcuts in crucial quality control tests and violating a raft of manufacturing standards. This case is believed to be a FCA whistleblower case though it has not been unsealed. Settlement negotiations are primed to conclude now that Lipitor has lost its patent protection and Ranbaxy is a manufacturer of generic Lipitor. It is time for this company to put its problems behind it and move on to greener pastures. Speculation regarding a settlement amount gathers around $400 million.
There are certainly other FCA cases out there. However, these cases alone could push fiscal 2012 over the $8 billion mark in total recoveries. Whistleblowers be encouraged and keep bringing your information forward.